The MAA are delighted to confirm that from 1 September 2022, Rituximab is now an unrestricted listing on both the S100 Highly Specialised Drugs Program and the S100 Efficient Funding of Chemotherapy Program. This means that the cost of this medication for people with Myasthenia Gravis will be covered via the PBS and that there is equitable access to this medication for the Australian Myasthenia community.
Congratulations to everyone who contributed to bringing this about. It is a very special day.